With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market in terms of revenue.
Players, stakeholders, and other participants in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market.
The following players are covered in this report:
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
Hospitals
Clinic
Others
Players, stakeholders, and other participants in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market.
The following players are covered in this report:
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
Hospitals
Clinic
Others
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Eculizumab
1.4.3 Methylprednisolone
1.4.4 Azathioprine
1.4.5 Mycophenolate Mofetil
1.4.6 Rituximab
1.5 Market by Application
1.5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2015-2026)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions
2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Devic’s Syndrome (Neuromyelitis Optica) Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Market Size
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2015-2020)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2019
3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.4 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.5 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2021-2026)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application (2015-2026)
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
6.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in North America (2019-2020)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
7.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Europe (2019-2020)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
8 China
8.1 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
8.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in China (2019-2020)
8.3 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
8.4 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
9.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Japan (2019-2020)
9.3 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
9.4 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
10.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
11 India
11.1 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
11.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in India (2019-2020)
11.3 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
11.4 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
12.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Alexion Pharmaceuticals, Inc.
13.1.1 Alexion Pharmaceuticals, Inc. Company Details
13.1.2 Alexion Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020))
13.1.5 Alexion Pharmaceuticals, Inc. Recent Development
13.2 Teva Pharmaceuticals
13.2.1 Teva Pharmaceuticals Company Details
13.2.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
13.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.2.5 Teva Pharmaceuticals Recent Development
13.3 Fresenius Kabi AG
13.3.1 Fresenius Kabi AG Company Details
13.3.2 Fresenius Kabi AG Business Overview and Its Total Revenue
13.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.3.5 Fresenius Kabi AG Recent Development
13.4 Pharmacia & Upjohn (a subsidary of Pfizer)
13.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
13.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview and Its Total Revenue
13.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
13.5 Lupin Ltd.
13.5.1 Lupin Ltd. Company Details
13.5.2 Lupin Ltd. Business Overview and Its Total Revenue
13.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.5.5 Lupin Ltd. Recent Development
13.6 Sagent Pharmaceuticals, Inc.
13.6.1 Sagent Pharmaceuticals, Inc. Company Details
13.6.2 Sagent Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.6.5 Sagent Pharmaceuticals, Inc. Recent Development
13.7 Zydus Pharmaceuticals, Inc.
13.7.1 Zydus Pharmaceuticals, Inc. Company Details
13.7.2 Zydus Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.7.5 Zydus Pharmaceuticals, Inc. Recent Development
13.8 Sandoz Inc. (Novartis)
13.8.1 Sandoz Inc. (Novartis) Company Details
13.8.2 Sandoz Inc. (Novartis) Business Overview and Its Total Revenue
13.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.8.5 Sandoz Inc. (Novartis) Recent Development
13.9 Alkem Laboratories Ltd.
13.9.1 Alkem Laboratories Ltd. Company Details
13.9.2 Alkem Laboratories Ltd. Business Overview and Its Total Revenue
13.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.9.5 Alkem Laboratories Ltd. Recent Development
13.10 Mylan Pharmaceuticals, Inc.
13.10.1 Mylan Pharmaceuticals, Inc. Company Details
13.10.2 Mylan Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.10.5 Mylan Pharmaceuticals, Inc. Recent Development
13.11 Hoffmann-La Roche/ Chugai Pharmaceutical
10.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
10.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview and Its Total Revenue
10.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
10.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
10.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
13.12 MedImmune LLC
10.12.1 MedImmune LLC Company Details
10.12.2 MedImmune LLC Business Overview and Its Total Revenue
10.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
10.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
10.12.5 MedImmune LLC Recent Development
13.13 RemeGen, Ltd.
10.13.1 RemeGen, Ltd. Company Details
10.13.2 RemeGen, Ltd. Business Overview and Its Total Revenue
10.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
10.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
10.13.5 RemeGen, Ltd. Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Eculizumab
1.4.3 Methylprednisolone
1.4.4 Azathioprine
1.4.5 Mycophenolate Mofetil
1.4.6 Rituximab
1.5 Market by Application
1.5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2015-2026)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions
2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Devic’s Syndrome (Neuromyelitis Optica) Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Market Size
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2015-2020)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2019
3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.4 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.5 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2021-2026)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application (2015-2026)
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
6.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in North America (2019-2020)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
7.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Europe (2019-2020)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
8 China
8.1 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
8.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in China (2019-2020)
8.3 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
8.4 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
9.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Japan (2019-2020)
9.3 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
9.4 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
10.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
11 India
11.1 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
11.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in India (2019-2020)
11.3 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
11.4 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
12.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Alexion Pharmaceuticals, Inc.
13.1.1 Alexion Pharmaceuticals, Inc. Company Details
13.1.2 Alexion Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020))
13.1.5 Alexion Pharmaceuticals, Inc. Recent Development
13.2 Teva Pharmaceuticals
13.2.1 Teva Pharmaceuticals Company Details
13.2.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
13.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.2.5 Teva Pharmaceuticals Recent Development
13.3 Fresenius Kabi AG
13.3.1 Fresenius Kabi AG Company Details
13.3.2 Fresenius Kabi AG Business Overview and Its Total Revenue
13.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.3.5 Fresenius Kabi AG Recent Development
13.4 Pharmacia & Upjohn (a subsidary of Pfizer)
13.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
13.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview and Its Total Revenue
13.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
13.5 Lupin Ltd.
13.5.1 Lupin Ltd. Company Details
13.5.2 Lupin Ltd. Business Overview and Its Total Revenue
13.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.5.5 Lupin Ltd. Recent Development
13.6 Sagent Pharmaceuticals, Inc.
13.6.1 Sagent Pharmaceuticals, Inc. Company Details
13.6.2 Sagent Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.6.5 Sagent Pharmaceuticals, Inc. Recent Development
13.7 Zydus Pharmaceuticals, Inc.
13.7.1 Zydus Pharmaceuticals, Inc. Company Details
13.7.2 Zydus Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.7.5 Zydus Pharmaceuticals, Inc. Recent Development
13.8 Sandoz Inc. (Novartis)
13.8.1 Sandoz Inc. (Novartis) Company Details
13.8.2 Sandoz Inc. (Novartis) Business Overview and Its Total Revenue
13.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.8.5 Sandoz Inc. (Novartis) Recent Development
13.9 Alkem Laboratories Ltd.
13.9.1 Alkem Laboratories Ltd. Company Details
13.9.2 Alkem Laboratories Ltd. Business Overview and Its Total Revenue
13.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.9.5 Alkem Laboratories Ltd. Recent Development
13.10 Mylan Pharmaceuticals, Inc.
13.10.1 Mylan Pharmaceuticals, Inc. Company Details
13.10.2 Mylan Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
13.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
13.10.5 Mylan Pharmaceuticals, Inc. Recent Development
13.11 Hoffmann-La Roche/ Chugai Pharmaceutical
10.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
10.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview and Its Total Revenue
10.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
10.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
10.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
13.12 MedImmune LLC
10.12.1 MedImmune LLC Company Details
10.12.2 MedImmune LLC Business Overview and Its Total Revenue
10.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
10.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
10.12.5 MedImmune LLC Recent Development
13.13 RemeGen, Ltd.
10.13.1 RemeGen, Ltd. Company Details
10.13.2 RemeGen, Ltd. Business Overview and Its Total Revenue
10.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
10.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
10.13.5 RemeGen, Ltd. Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
